Axsome Therapeutics, Inc.

AXSM

$208.35

-0.75%

N/A-$1.57

Healthcare

Biotechnology

NASDAQ

Active Trading

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) ...

Fundamental Analysis of AXSM

Key Strengths

Multiple late-stage pipeline candidates addressing large CNS markets (depression, migraine, narcolepsy, fibromyalgia, Alzheimer's agitation)

Two approved and commercialized products (Sunosi, Symbravo) driving robust revenue growth

Risk Factors

Chronic unprofitability and negative cash flows, raising concerns about long-term financial sustainability

Heavy reliance on successful pipeline development; any clinical trial failures could severely impact the stock

Profitability

Net Margin-24.68%

Operating Margin-24.28%

Valuation

P/E Ratio-55.56x

Current Ratio1.43

Efficiency

ROE-255.60%

ROA-25.17%

Fundamental Analysis of AXSM

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system (CNS) disorders. The company has a promising pipeline including AXS-05 for major depressive disorder, treatment-resistant depression, and Alzheimer's disease agitation; AXS-07 for migraine; AXS-12 for narcolepsy; and AXS-14 for fibromyalgia. Axsome has successfully commercialized two products, Sunosi and Symbravo, generating substantial revenue growth. The company's financials show strong gross margins (93.2%) and rapid revenue expansion, but it remains unprofitable with negative net margins, operating margins, and free cash flow. The balance sheet reveals high leverage with a debt-to-equity ratio of 2.631, but the current ratio is adequate at 1.426. The company's beta of 0.596 indicates lower volatility compared to the market. Key strengths include a robust pipeline targeting large unmet medical needs, successful product launches, and a strong intellectual property portfolio. However, risks include dependency on pipeline success, regulatory hurdles, intense competition, high cash burn, and significant dilution risk. The stock trades at a high price-to-sales ratio of 14.1, reflecting optimistic growth expectations. Long-term prospects depend on pipeline execution and achieving profitability.

Key Strengths of AXSM

Multiple late-stage pipeline candidates addressing large CNS markets (depression, migraine, narcolepsy, fibromyalgia, Alzheimer's agitation)
Two approved and commercialized products (Sunosi, Symbravo) driving robust revenue growth
High gross margin of over 90%, indicating strong pricing power and manufacturing efficiency
Low beta (0.596) suggesting lower systematic risk relative to the broader market
Significant market opportunity with few effective treatments for many CNS disorders
Experienced leadership team with deep CNS expertise

Risk Factors of AXSM

Chronic unprofitability and negative cash flows, raising concerns about long-term financial sustainability
Heavy reliance on successful pipeline development; any clinical trial failures could severely impact the stock
High debt levels (debt-to-equity of 2.631) may strain cash resources and limit financial flexibility
Intense competition from larger pharmaceutical companies with more resources
Regulatory and safety issues; Symbravo carries a boxed warning for cardiovascular risks, and FDA scrutiny may delay approvals
Potential share dilution to fund operations and development

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$10.72B

-55.6x

P/E Ratio

13.8x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin93.24%

Net Profit Margin-24.68%

Debt/Equity Ratio2.63

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of AXSM

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of AXSM

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	-23.50%	—	—	Flat
Operating Margin	—	-22.73%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of AXSM

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	1.426	—	—	Flat
Quick Ratio	—	1.344	—	—	Flat
Debt / Equity	—	2.631	—	—	Flat

Valuation of AXSM

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-61.81x	—	—	Flat
P/B	—	151.32x	—	—	Flat

Supply Chain of AXSM

RELATIONS

Upstream

Contract Manufacturing Organizations (CMOs — small molecule oral solid dose)Active Pharmaceutical Ingredient (API) Suppliers — Dextromethorphan HBr, Bupropion HCl, Solriamfetol, Meloxicam, RizatriptanJazz Pharmaceuticals plc (legacy Sunosi supply chain)NASDAQ:JAZZ Pfizer Inc.NYSE:PFEAntecip Bioventures II LLCThird-Party Logistics Providers (3PLs)Excipient & Packaging Material Suppliers

Downstream

Cencora, Inc. (formerly AmerisourceBergen)NYSE:COR Cardinal Health, Inc.NYSE:CAH McKesson CorporationNYSE:MCKPharmanoviaGroup Purchasing Organizations (GPOs)Teva Pharmaceutical Industries Ltd.NYSE:TEVASpecialty & Retail Pharmacies (CVS, Walgreens, Rite Aid, independent pharmacies)

Proxies

Jazz Pharmaceuticals plcNASDAQ:JAZZ Harmony Biosciences Holdings, Inc.NASDAQ:HRMY Sage Therapeutics, Inc.NASDAQ:SAGE Catalent, Inc.NYSE:CTLT Thermo Fisher Scientific Inc.NYSE:TMO

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer